![]() | Only 14 pages are availabe for public view |
Abstract The diagnosis of CIPN is mainly clinical. In addition, several toxicity grading scales have been developed to assess the severity of peripheral neurotoxicity with the NCI-CTCAE (Common Terminology Criteria for Adverse Events) being the most commonly used one. On the other hand, the role of electroneurography and electromyography is controversial and their value seems to be confined to determination of the nature of neuropathy, but not the grade or severity of neurotoxicity. Treatment of CIPN should be based on prevention and symptomatic relief. Several trials have been proposed aiming at the prevention of development of peripheral neurotoxicity, but none of them was able to develop an effective drug for prevention or treatment of established chronic neurotoxicity. |